Patents by Inventor Adam Jan Sanderson

Adam Jan Sanderson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CGRP receptor antagonists
    Patent number: 11066386
    Abstract: The present invention provides compounds of Formula II or a pharmaceutically acceptable salts thereof, useful as a CGRP receptor antagonist.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: July 20, 2021
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Simon James Richards, Adam Jan Sanderson
  • CGRP RECEPTOR ANTAGONISTS
    Publication number: 20200181111
    Abstract: The present invention provides compounds of Formula II or a pharmaceutically acceptable salts thereof, useful as a CGRP receptor antagonist.
    Type: Application
    Filed: May 8, 2018
    Publication date: June 11, 2020
    Inventors: David Andrew Coates, Simon James Richards, Adam Jan Sanderson
  • Selective BACE1 inhibitors
    Patent number: 10011610
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: July 3, 2018
    Assignee: Eli Lilly and Company
    Inventors: David Michael Remick, Simon James Richards, Adam Jan Sanderson
  • Selective BACE1 inhibitors
    Patent number: 9938266
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: April 10, 2018
    Assignee: Eli Lilly and Company
    Inventor: Adam Jan Sanderson
  • SELECTIVE BACE1 INHIBITORS
    Publication number: 20180030044
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 11, 2016
    Publication date: February 1, 2018
    Applicant: Eli Lilly and Compny
    Inventor: Adam Jan Sanderson
  • Selective BACE1 Inhibitors
    Publication number: 20160318953
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 22, 2016
    Publication date: November 3, 2016
    Inventors: David Michael Remick, Simon James Richards, Adam Jan Sanderson
  • Purine compounds
    Patent number: 8759360
    Abstract: A compound of the formula: and pharmaceutical compositions for the treatment or prevention of pain.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: June 24, 2014
    Assignee: Eli Lilly and Company
    Inventors: Adam Jan Sanderson, Peter Charles Astles, Rossella Guidetti, Sean Patrick Hollinshead
  • Substituted [(5-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HTantagonists
    Patent number: 8314092
    Abstract: A dual H1/5-HT2A receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: November 20, 2012
    Assignee: Eli Lilly and Company
    Inventors: Anne Marie Camp, Peter Thaddeus Gallagher, Andrew James Ledgard, Adam Jan Sanderson, David Andrew Coates
  • SUBSTITUTED [(5H-PYRROLO[2,1-c][1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS
    Publication number: 20120202797
    Abstract: A dual H1/5-HT2A receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Application
    Filed: January 25, 2012
    Publication date: August 9, 2012
    Applicant: Eli Lilly and Company
    Inventors: Anne Marie CAMP, Peter Thaddeus GALLAGHER, Andrew James LEDGARD, Adam Jan SANDERSON, David Andrew COATES
  • PURINE COMPOUNDS
    Publication number: 20110245255
    Abstract: A compound of the formula: and pharmaceutical compositions for the treatment or prevention of pain.
    Type: Application
    Filed: March 28, 2011
    Publication date: October 6, 2011
    Inventors: Adam Jan SANDERSON, Peter Charles ASTLES, Rossella GUIDETTI, Sean Patrick HOLLINSHEAD
  • Aza-cyclic compounds as modulators of acetylcholine receptors
    Patent number: 7408067
    Abstract: Compounds comprising an aza-cyclic portion and an aromatic portion linked via a sulphur atom are disclosed. The compounds disclosed are selective modulators of beta 4 subtype nicotinic acetylcholine receptors and are useful for the treatment of dysfunctions of the central and autonomic nervous systems.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: August 5, 2008
    Assignee: Merck + Co., Inc.
    Inventors: Peter Charles Astles, Stephen Richard Baker, Celine Bonnefous, Jean Michel Vernier, Martine Keenan, Adam Jan Sanderson
  • Modulators of acetylcholine receptors
    Patent number: 7148236
    Abstract: The present invention relates to compounds that modulate neurotransmission by promoting the release of neurotransmitters such as acetylcholine, dopamine and norepinephrine. More particularly, the present invention relates to thio-bridged aryl compounds that are capable of modulating acetylcholine receptors and pharmaceutical compositions comprising such compounds. The compounds disclosed are useful for the treatment of dysfunctions of the central and autonomic nervous systems.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: December 12, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Peter Charles Astles, Stephen Richard Baker, Rowena Villanueva Cube, Jose Antonio Martinez-Perez, Ana Isabel Mateo Herranz, Jean Michel Vernier, Colin Peter Dell, Sonia Gutierrez, Lourdes Prieto, Martine Keenan, Adam Jan Sanderson, Colin William Smith